ARCH THERAPEUTICS, INC.: 10-Q filed 2022-05-13
What ARCH THERAPEUTICS, INC. reported in its quarterly report filed 2022-05-13 (fiscal Q2 2022): 31 published measures, 86 facts as tagged in accession 0001851734-22-000246.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2022-05-13
- Fiscal period
- fiscal Q2 2022
- Accession
- 0001851734-22-000246 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ARCH THERAPEUTICS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 1,439,376 | USD | |
| At 2021-09-30 | 3,676,485 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 4,498,800 | USD | |
| At 2021-09-30 | 4,702,159 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | -3,059,424 | USD | |
| At 2021-12-31 | -2,423,678 | USD | |
| At 2021-09-30 | -1,025,674 | USD | |
| At 2021-03-31 | 2,051,682 | USD | |
| At 2020-12-31 | -2,568,984 | USD | |
| At 2020-09-30 | -1,500,491 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | -790,318 | USD | 90 |
| 2021-10-01 to 2022-03-31 | -2,340,465 | USD | 182 |
| 2021-01-01 to 2021-03-31 | -1,791,296 | USD | 90 |
| 2020-10-01 to 2021-03-31 | -2,945,400 | USD | 182 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-10-01 to 2022-03-31 | -2,212,234 | USD | 182 |
| 2020-10-01 to 2021-03-31 | -2,664,451 | USD | 182 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-10-01 to 2022-03-31 | 0 | USD | 182 |
| 2020-10-01 to 2021-03-31 | 3,275 | USD | 182 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-10-01 to 2022-03-31 | 0 | USD | 182 |
| 2020-10-01 to 2021-03-31 | 7,269,233 | USD | 182 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-10-01 to 2022-03-31 | 0 | USD | 182 |
| 2020-10-01 to 2021-03-31 | -3,275 | USD | 182 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | -52,137,384 | USD | |
| At 2021-09-30 | -49,796,919 | USD |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | 0 | USD/shares | 90 |
| 2021-10-01 to 2022-03-31 | -0.01 | USD/shares | 182 |
| 2021-01-01 to 2021-03-31 | -0.01 | USD/shares | 90 |
| 2020-10-01 to 2021-03-31 | -0.01 | USD/shares | 182 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 3,642 | USD | |
| At 2021-09-30 | 5,240 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-10-01 to 2022-03-31 | 306,715 | USD | 182 |
| 2020-10-01 to 2021-03-31 | 278,340 | USD | 182 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | -1,750,866 | USD | 90 |
| 2021-10-01 to 2022-03-31 | -3,260,684 | USD | 182 |
| 2021-01-01 to 2021-03-31 | -1,750,546 | USD | 90 |
| 2020-10-01 to 2021-03-31 | -2,984,328 | USD | 182 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 1,432,234 | USD | |
| At 2021-09-30 | 3,667,745 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | 39,452 | USD | 90 |
| 2021-10-01 to 2022-03-31 | 79,781 | USD | 182 |
| 2021-01-01 to 2021-03-31 | 40,750 | USD | 90 |
| 2020-10-01 to 2021-03-31 | 70,016 | USD | 182 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 1,444,407 | USD | |
| At 2021-09-30 | 1,727,547 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 1,288,078 | USD | |
| At 2021-09-30 | 408,083 | USD |
Net inventory
Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 1,197,568 | USD | |
| At 2021-12-31 | 1,197,568 | USD | |
| At 2021-09-30 | 1,093,765 | USD | |
| At 2020-12-31 | 1,093,765 | USD |
Cost of revenue
Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | 17,430 | USD | 90 |
| 2021-10-01 to 2022-03-31 | 34,223 | USD | 182 |
| 2021-01-01 to 2021-03-31 | 10,102 | USD | 90 |
| 2020-10-01 to 2021-03-31 | 10,102 | USD | 182 |
Selling, general and administrative expense
Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | 1,208,910 | USD | 90 |
| 2021-10-01 to 2022-03-31 | 2,472,013 | USD | 182 |
| 2021-01-01 to 2021-03-31 | 1,339,833 | USD | 90 |
| 2020-10-01 to 2021-03-31 | 2,230,024 | USD | 182 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | 527,656 | USD | 90 |
| 2021-10-01 to 2022-03-31 | 762,274 | USD | 182 |
| 2021-01-01 to 2021-03-31 | 410,611 | USD | 90 |
| 2020-10-01 to 2021-03-31 | 754,202 | USD | 182 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 237,069,770 | shares | |
| At 2021-09-30 | 236,719,770 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 48,841,040 | USD | |
| At 2021-09-30 | 48,534,525 | USD |
Gross property, plant and equipment
Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 33,756 | USD | |
| At 2021-09-30 | 33,756 | USD |
Accumulated depreciation on property, plant and equipment
Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 30,114 | USD | |
| At 2021-09-30 | 28,516 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 3,500 | USD | |
| At 2021-09-30 | 3,500 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-03-31 | 180,261 | USD | |
| At 2021-09-30 | 307,341 | USD |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | 799 | USD | 90 |
| 2021-10-01 to 2022-03-31 | 1,598 | USD | 182 |
| 2021-01-01 to 2021-03-31 | 617 | USD | 90 |
| 2020-10-01 to 2021-03-31 | 989 | USD | 182 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-01-01 to 2022-03-31 | 960,548 | USD | 90 |
| 2021-10-01 to 2022-03-31 | 920,219 | USD | 182 |
| 2021-01-01 to 2021-03-31 | -40,750 | USD | 90 |
| 2020-10-01 to 2021-03-31 | 38,928 | USD | 182 |
Change in inventories
The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-10-01 to 2022-03-31 | 351,876 | USD | 182 |
| 2020-10-01 to 2021-03-31 | 42,215 | USD | 182 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-10-01 to 2022-03-31 | 879,995 | USD | 182 |
| 2020-10-01 to 2021-03-31 | 216,783 | USD | 182 |
Inspect the source
- Entity
- ARCH THERAPEUTICS, INC. / CIK 0001537561
- Captured
- SEC response SHA-256
63d0e84748ee59ab7c6817be68d0a32b23d83273213bc50081bb86253a1d4cc2
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001537561.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))